Persistent tumor cells in bone marrow of non-metastatic breast cancer patients after primary surgery are associated with inferior outcome

[1]  W. Woodward,et al.  Primary breast cancer patients with high risk clinicopathologic features have high percentages of bone marrow epithelial cells with ALDH activity and CD44⁺CD24lo cancer stem cell phenotype. , 2011, European Journal of Cancer.

[2]  T. Fehm,et al.  Persistence of Disseminated Tumor Cells in the Bone Marrow of Breast Cancer Patients Predicts Increased Risk for Relapse—A European Pooled Analysis , 2011, Clinical Cancer Research.

[3]  F. Shammas,et al.  Disseminated tumor cells in bone marrow assessed by TWIST1, cytokeratin 19, and mammaglobin A mRNA predict clinical outcome in operable breast cancer patients. , 2010, Clinical breast cancer.

[4]  W. Gianni,et al.  Cancer stem cells and epithelial-mesenchymal transition: revisiting minimal residual disease. , 2010, Current cancer drug targets.

[5]  P. V. van Dam,et al.  Circulating tumour cell detection: a direct comparison between the CellSearch System, the AdnaTest and CK-19/mammaglobin RT–PCR in patients with metastatic breast cancer , 2009, British Journal of Cancer.

[6]  S. Agelaki,et al.  Detection of cytokeratin-19 mRNA-positive cells in the peripheral blood and bone marrow of patients with operable breast cancer , 2009, British Journal of Cancer.

[7]  Jan Terje Kvaløy,et al.  A small subgroup of operable breast cancer patients with poor prognosis identified by quantitative real-time RT-PCR detection of mammaglobin A and trefoil factor 1 mRNA expression in bone marrow , 2009, Breast Cancer Research and Treatment.

[8]  G. Kallergi,et al.  Prognostic Value of the Molecular Detection of Circulating Tumor Cells Using a Multimarker Reverse Transcription-PCR Assay for Cytokeratin 19, Mammaglobin A, and HER2 in Early Breast Cancer , 2008, Clinical Cancer Research.

[9]  T. Kroll,et al.  Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  F. Shammas,et al.  Bone marrow cytokeratin 19 mRNA level is an independent predictor of relapse-free survival in operable breast cancer patients , 2008, Breast Cancer Research and Treatment.

[11]  R. Bast,et al.  American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  A. Giuliano,et al.  Most Early Disseminated Cancer Cells Detected in Bone Marrow of Breast Cancer Patients Have a Putative Breast Cancer Stem Cell Phenotype , 2006, Clinical Cancer Research.

[13]  T. Fehm,et al.  A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation , 2006, Cancer.

[14]  T. Fehm,et al.  Detection of cytokeratin-positive cells in the bone marrow of breast cancer patients undergoing adjuvant therapy , 2006, Breast Cancer Research and Treatment.

[15]  J. Nesland,et al.  Comparison of the clinical significance of occult tumor cells in blood and bone marrow in breast cancer , 2006, International journal of cancer.

[16]  P. Dam,et al.  Real time RT-PCR detection of disseminated tumour cells in bone marrow has superior prognostic significance in comparison with circulating tumour cells in patients with breast cancer , 2006 .

[17]  E. van Marck,et al.  Real-time RT–PCR detection of disseminated tumour cells in bone marrow has superior prognostic significance in comparison with circulating tumour cells in patients with breast cancer , 2006, British Journal of Cancer.

[18]  Douglas G Altman,et al.  Reporting recommendations for tumor marker prognostic studies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  T. Fehm,et al.  A pooled analysis of bone marrow micrometastasis in breast cancer. , 2005, The New England journal of medicine.

[20]  Takuji Tanaka,et al.  An evaluation of the integration of non-traditional learning tools into a community based breast and cervical cancer education program: The witness project of Buffalo , 2003, BMC Cancer.

[21]  K. Pantel,et al.  Circulating Tumor Cells in Breast Cancer: Correlation to Bone Marrow Micrometastases, Heterogeneous Response to Systemic Therapy and Low Proliferative Activity , 2005, Clinical Cancer Research.

[22]  Michael Dean,et al.  Tumour stem cells and drug resistance , 2005, Nature Reviews Cancer.

[23]  H. Graham,et al.  Persistence of bone marrow micrometastases in patients receiving adjuvant therapy for breast cancer: Results at 4 years , 2005, International journal of cancer.

[24]  S. Braun,et al.  The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence , 2005, Cancer.

[25]  J. Nesland,et al.  Isolated Tumor Cells in Bone Marrow Three Years after Diagnosis in Disease-Free Breast Cancer Patients Predict Unfavorable Clinical Outcome1 , 2004, Clinical Cancer Research.

[26]  J. Nesland,et al.  The Prognostic Value of Isolated Tumor Cells in Bone Marrow in Breast Cancer Patients , 2004, Clinical Cancer Research.

[27]  G Kvalheim,et al.  Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  S. Braun,et al.  The fate and prognostic value of occult metastatic cells in the bone marrow of patients with breast carcinoma between primary treatment and recurrence , 2001, Cancer.

[29]  T. Dimpfl,et al.  Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. , 2000, The New England journal of medicine.

[30]  J. V. Van eekelen,et al.  Sensitive and quantitative one-step polymerase chain reaction using capillary electrophoresis and fluorescence detection for measuring cytokeratin 19 expression. , 1999, Scandinavian journal of clinical and laboratory investigation.

[31]  S. Braun,et al.  Re: Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. , 1996, Journal of the National Cancer Institute.

[32]  K. Pantel,et al.  Cancer micrometastases , 2009, Nature Reviews Clinical Oncology.

[33]  R. Holle,et al.  Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. , 1996, Journal of the National Cancer Institute.